Both antiVEGFR3 mAb, which specifically targets LEC growth receptors, and sunitinib, which inhibits the kinase activity of VEGFR3
Equally antiVEGFR3 mAb, which particularly targets LEC growth receptors, and sunitinib, which inhibits the kinase exercise of VEGFR3, inhibited islet lymphangiogenesis, lowered or prevented reduction of insulin+ cells and diminished…